AT Research Partners

Spermicide Uses Nanoparticles and Chemotaxis for Discreet, OTC Product GREENSBORO, N.C., April 13, 2022 /PRNewswire/ — AT Research Partners has been granted US patent #11,298,375, Brady, et.al. for a contraceptive breakthrough targeting spermatozoa, the “weakest link” in reproduction. The patent was pro se filed and granted in 6 months at a fraught family planning moment, when Texas and other…

GREENSBORO, N.C., Nov. 15, 2021 /PRNewswire/ — A United States patent has been filed for an unprecedented application of nanoparticles as a safe, effective and discreet contraceptive. One of the patent-pending formulations would allow for continuous protection from as few as 2 applications per week with a biologically neutral contraceptive. Read the Press Release Here: https://www.prnewswire.com/news-releases/novel-contraceptive-by-at-research-partners-promises-efficacy-access-and-safety-for-women-using-nanotechnology-301423284.html

Researchers from Kepley BioSystems have invented the means to “permanently infuse” reusable substrates such as personal protective equipment (PPE) and medical garments with antimicrobial functional fullerenes that could withstand cleaning. These fullerenes are developed to bind to and inactivate pathogens such as viruses, fungi, and bacteria, potentially SARS-CoV-2, the company reported in a news release.…